Q1 2026 Veru Inc Earnings Call Transcript

Feb 11, 2026 / 01:00 PM GMT

Release Date Price: $2.3 (-0.43%)

Transcript 10-Q8-K

Key Points

Positve

Veru Inc (VERU) successfully completed a Phase 2B clinical trial demonstrating that Enovosarm, in combination with GLP-1 receptor agonists, can lead to selective fat loss while preserving lean mass in older patients with obesity.
The FDA has provided regulatory clarity for the development of Enovosarm, offering two potential pathways for approval based on weight loss and preservation of physical function.
Veru Inc (VERU) completed a public offering, raising approximately $23.4 million, which strengthens its financial position.
Research and development costs decreased significantly, indicating a more efficient allocation of resources.
The company's cash and cash equivalents increased to $33 million, providing a solid financial foundation for future operations.

Negative

Veru Inc (VERU) reported a net loss of $5.3 million for the quarter, indicating ongoing financial challenges.
The company is not yet profitable and continues to experience negative cash flow from operations.
There is uncertainty regarding the efficacy of Enovosarm in achieving more than 5% incremental weight loss, which could impact regulatory approval.
The reliance on future clinical trials for Enovosarm introduces risks related to trial outcomes and regulatory hurdles.
The sale of the FC-2 female condom business has resulted in discontinued operations, which may affect future revenue streams.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VERU.OQ - Veru Inc
Q1 2026 Veru Inc Earnings Call
Feb 11, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to Veru Inc.s. Investors conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the key followed by 0. After this morning's discussion, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference call over to Mr. SAM Fish. Varus Inc's executive Director, Investor relations and corporate communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning. The statements made on this

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.